Clinical Trial Update: Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating 0.1% Uracil Topical Cream for prevention of hand-foot syndrome in breast cancer patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Palmar-plantar Erythrodysesthesia

Drugs mentioned

• 0.1% Uracil Topical Cream (uracil topical cream)

Snippet

Sponsor: Nanometics (d.b.a. PHD Biosciences) | Conditions: Palmar-Plantar Erythrodysesthesia, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED